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Abstract: Seventy-four consecutive pediatric liver transplant recipients 
were reviewed to assess the effect of the monoclonal anti-T-Iymphocyte 
antibody OKT3 on subsequent viral infection (9 patients were excluded 
due to postoperative demise during the 1st week). Twenty-two patients 
received OKT3 in addition to standard cyclosporine-prednisone immuno-
suppression for either steroid-resistant acute rejection (18) or to facilitate 
reduction of cyclosporine due to severe renal impairment (4). Invasive 
infections were diagnosed by histology or culture in tissue biopsies or 
bronchoalveolar lavage specimens. The overall incidence of viral infection 
was 58%, half of which was due to cytomegalovirus (CMV). Invasive 
viral disease was associated with increased mortality (37% vs. 3% p = 
0.001). Viral-related deaths were due to CMV (5), disseminated adenovi-
rus (3), disseminated enterovirus (1) and respiratory syncytial viral pneu-
monia (1). The use of OKT3 was associated with increased viral disease 
(59% vs, 33% p=0,04) and invasive primary CMV disease (58% vs, 19% 
p=O.04). Trends were observed toward increased overall viral infection 
(73% vs, 51 % p=O,08), primary CMV infection (58% vs. 25% p=0.08) 
and overall mortality (27% vs. 9% p =0.08) following OKT3 therapy. We 
conclude that pediatric liver transplant recipients who require OKT3 
therapy may be at increased risk for invasive viral disease and especially 
invasive primary CMV disease. 
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Viral infections, especially cytomegalovirus 
(CMV), are a significant cause of morbidity and 
mortality following solid organ transplantation 
(1-3). Renal (4--8) and cardiac (9) transplant recipi-
ents treated with antilymphocyte globulin and anti-
thymocyte globulin have experienced an increased 
incidence of viral infections compared with patients 
receiving other immunosuppressive regimens. Simi-
lar data are unavailable for liver transplant recipi-
ents prior to 1980 due to limited overall survival in 
patients treated with the azathioprine-prednisone-
antilymphocyte globulin regimen prior to the use 
of cyclosporine (10, 11). Antilymphocyte prepara-
tions have been used only sporadically following 
the dramatic success of liver transplantation with 
the cyclosporine-prednisone regimen. The recent 
introduction of the murine monoclonal anti-T-
lymphocyte antibody OKT3 (Ortho Pharmaceut-
ical, Raritan, NJ) proved to be highly effective in 
the salvage of steroid-resistant acute rejection of 
kidney, liver and heart transplants (12). The use 
of OKT3 in adult liver transplant recipients has 
recently been associated with an increased fre-
quency of viral infections (13). The most recent 
report of viral infections in pediatric liver trans-
plant recipients at this institution summarized data 
prior to the use of OKT3 (14). This study was 
performed to assess the effect of OKT3 therapy on 
subsequent viral disease in pediatric liver trans-
plant recipients. 
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Study population 
The patient population consisted of all 74 consecu-
tive pediatric patients (age 17 yr or younger) who 
underwent primary orthotopic liver transplan-
tation at the Children's Hospital of Pittsburgh dur-
ing the calendar year 1987. Patients who died either 
intraoperatively (2 patients) or within the first 7 
postoperative days (7 patients) were excluded from 
evaluation, leaving a study population of 65 pa-
tients. None of the excluded patients received 
OKT3 and no evidence of viral infection was found 
at autopsy. Half of the 65 patients were less than 
3 yr old. The mean age was 5.1 yr (standard devi-
ation 4.5 yr). Indications for transplantation in-
cluded biliary atresia/hypoplasia (46), inborn er-
rors of metabolism (6), cirrhosis (5), acute fulmin-
ant hepatitis (4), tumors (3) and sclerosing 
cholangitis (l). Forty-four patients had undergone 
previous abdominal operations, 37 of which were 
Kasai procedures. 
All patients underwent orthotopic liver trans-
plantation as described previously (15) either with 
a Roux-en-y choledochojejunostomy or, where 
feasible, primary end-to-end bile duct anastomosis 
with T-tube drainage. Matching of recipient and 
donor by CMV serologic status was not under-
taken prior to transplant. Blood products were 
not routinely screened for evidence of CMY. The 
majority of blood transfusions were administered 
during the initial transplant operation. 
The medical records of all patients were reviewed 
for the use of OKT3 as well as clinical and labora-
tory evidence of viral infections. Follow-up ranged 
from 6 to 18 months (mean 12 months) ending 1 
July 1988. 
Immunosuppression 
Standard immunosuppression consisted of intra-
operative intravenous cyclosporine (2 mg/kg) and 
methylprednisolone (500 mg) following reperfusion 
of the new liver. Intravenous cyclosporine (6 mg/ 
kg/d) was administered postoperatively. Oral 
cyclosporine was added as soon as possible to 
maintain whole blood radioimmunoassay trough 
levels of 800 to 1000 ng/ml. Methylprednisolone 
was rapidly tapered during the postoperative 
period from 100 mg/d to 20 mg/d by decrements 
of 20 mg daily. Oral prednisone (20 mg/d) was 
begun as soon as enteral feedings were tolerated. 
The dose of prednisone was further reduced as 
dictated by clinical response. Occasional patients 
were begun on azathioprine when usual dosages of 
cyclosporine were associated with excessive side-
effects such as nephrotoxicity or refractory hyper-
tension. 
Suspected acute rejection episodes manifested by 
transaminase and/or bilirubin elevation were 
treated empirically with 1 g intravenous hydrocor-
tisone. Unresponsive episodes of acute rejection 
were diagnosed histologically by percutaneous 
needle biopsy revealing typical portal lymphocytic 
infiltrates with ductular invasion (16). Treatment 
consisted of a 5-d cycle of tapering dosage of intra-
venous methylprednisolone (100 mg/d down to 20 
mg/d). Steroid-resistant rejection was then treated 
with a l4-d course of intravenous OKT3 (2 to 5 
mg daily) and discontinuation of the steroid cycle 
(17). Additionally, 4 patients with severe renal im-
pairment in the immediate postoperative period 
OKT3 and viral disease in liver Tx 
were given OKT3 to permit reduction of the cyclo-
sporine dose. 
Antibiotic prophylaxis 
Ampicillin and cefotaxime (both at a dose of 100 
mg/kg/d) were administered intravenously pre-
operatively and for the first 5 d postoperatively. 
Mai"ntenance postoperative medications included 
oral nystatin (400000 units every 6 hours) for fun-
gal prophylaxis and trimethoprim-sulfamethox-
azole (20-40 mg oftrimethoprim daily) for prophy-
laxis of Pneumocystis carinii pneumonia. Intra-
venous immunoglobulin and acyclovir were not 
used prophylactically. Ganciclovir was adminis-
tered on a compassionate use basis for biopsy-
proven invasive CMV disease beginning in August 
1987 and throughout the remainder of the study 
(approved by the Human Rights Committee of 
Children's Hospital of Pittsburgh). 
Viral infections 
Viral infections were diagnosed by either culture, 
serology or histopathology in combination with 
clinical observations. All donors were screened for 
CMV. Surveillance serologies for CMV, Herpes 
simplex virus (HSV) and Epstein-Barr virus (EBV), 
as well as viral cultures of buffy coat, throat and 
urine were obtained preoperatively when possible. 
Additional samples were obtained when clinically 
indicated. Viral cultures were performed as pre-
viously described (14). CMV serologies were ini-
tially performed by anticomplement immunofluor-
escence (18); more recently, CMV antibody was 
determined with a solid-phase immunofluorescence 
(19). Viral infections were considered invasive if 
the virus was demonstrated by either culture or 
histology in a tissue biopsy or bronchoalveolar 
lavage specimen. EBV-associated posttransplant 
lymphoproliferative disorders (PTLD) were diag-
nosed on the basis of histopathology and serology 
(20). 
Statistical analysis 
Observed proportions were compared with the 
Chi-square test or two-tailed Fisher's Exact Test 
for small samples. Calculated means were com-
pared by Student's t-test. The hierarchical log lin-
ear model was used to examine the possible com-
bined associations of OKT3 therapy, retransplan-
tation and development of viral infection. This 
analysis was intended to generate models rather 
than to test a particular hypothesis (21) and was 
performed utilizing BMDP4F Software (BMDP 
Statistical Software, Inc. Los Angeles, CA). 
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Results 
Viral infection 
Fifty-three viral infections occurred in 58% (38/ 
65) of patients. CMV accounted for half (26/53) of 
these episodes. The remainder were caused by HSV 
(7), respiratory syncytial virus (RSV) (5), adenovi-
rus (5), rotavirus (4), EBV (3), parainfluenzae (2) 
and enterovirus (1). The mortality rate in patients 
with viral infection was 26% (10/38) compared to 
4% (1/27) in patients who did not develop viral 
infection (p = 0.017). 
Thirty invasive viral infections occurred in 42% 
(27/65) of patients between 9 and 117 d following 
liver transplantation (mean 42 d). CMV was re-
sponsible for 70% (21/30) of these episodes. The 
remainder were caused by adenovirus (4), EBV (3), 
enterovirus (1) and RSV (1). The most frequent 
sites of visceral involvement were the liver (51 %) 
and the lungs (30%). Mortality following invasive 
viral infection was 37% (10/27) compared with 
only 3% (1/38) for those who did not develop 
invasive infection (p < 0.001). Nine deaths were di-
rectly due to complications of viral infection, in-
cluding CMV pneumonia (3), CMV cerebritis (1), 
disseminated adenoviral hepatitis (3), RSV pneu-
monia (1) and combined enteroviral/polymicrobial 
sepsis (1). Another patient developed severe CMV 
pneumonia and hepatitis resulting in a rejection 
episode that necessitated retransplantation. This 
patient subsequently died of complications of re-
transplantation. 
OKT3 was administered to 22 of the 65 patients 
in this study. The proportion of patients who de-
veloped viral infections following OKT3 therapy 
was greater than in those who did not receive 
OKT3 (73% vs. 51 % p=0.08), as was the pro-
portion of patients who developed invasive viral 
disease following OKT3 (59% vs. 33% p=0.04). 
An increased mortality rate was observed in those 
patients who received OKT3 compared with those 
who did not (27% vs. 9% p = 0.08). The case-
fatality rate of patients who developed invasive 
viral infection was similar for patients who received 
OKT3 and for those who did not (6/13 vs. 4/14, 
p=0.35). 
Thirteen patients required retransplantation 
within 3 months of the primary liver transplant 
operation. The proportion of these patients who 
developed viral infections was greater than in the 
single transplant recipients (92% vs. 51 % p= 
0.016). Similarly, invasive viral disease appeared 
to be more common in the retransplanted group 
compared with the single transplant group (69% 
vs. 36% p =0.10). Mortality following retransplan-
tation was 31 % compared to 11 % after a single 
transplant (p = 0.11). 
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The frequency of viral infection and invasive 
viral infection as a function of prior treatment 
with OKT3 and retransplantation was evaluated 
utilizing a hierarchical log linear model. The model 
that best fit these data for viral infections included 
independent effects of both OKT3 treatment and 
retransplantation, as well as interaction terms be-
tween OKT3 treatment and viral infections and 
retransplantation and viral infection; no interac-
tion was found between OKT3 and retransplan-
tation (df = 2, likelihood ratio Chi-square = 0.80, 
p=0.67). A similar model was found for invasive 
viral disease (df = 2, likelihood ratio Chi-square = 
3.8, p=0.15). These models suggest that both treat-
ment with OKT3 and retransplantation indepen-
dently predict an increased risk of developing viral 
infection and invasive viral disease. 
CMV disease 
The overall rate of CMV infection was 40% (26/ 
65); 81 % (21/26) of these infections were invasive. 
Twenty-four percent (5/21) of invasive cases were 
fatal. The mean interval from transplantation to 
diagnosis of invasive CMV disease was 37 d (range 
9-117) and this interval was not affected by the 
use ofOKT3. Invasive CMV disease was diagnosed 
at a mean of 24 d (range 7-61) following adminis-
tration of OKT3. The timing of OKT3 therapy 
following transplantation (mean 10 d) was not dif-
ferent among those patients who subsequently de-
veloped invasive CMV disease and those who did 
not. The mean interval from transplantation to 
diagnosis of CMV was longer in survivors com-
pared with nonsurvivors (41 vs. 25 d, p=0.05). 
CMV infection developed in 50% (11/22) of 
OKT3 recipients as compared to 35% (15/43) of 
untreated patients (p = 0.18). Invasive CMV dis-
ease was more common among the OKT3 recipi-
ents compared with those who did not receive 
OKT3 (10/22 vs. 11/43, p=0.09). The case-fatality 
Table 1. Effect of OKT3 on CMV infection following pediatric liver transplan-






Pretransplant CMV serology 
CMV-negative 




7/12 (58) 3/16 (19) 
p=0.04 
3/ 7 (43) 1/ 4 (25) 
NS 
3/12 (25) 1/16 ( 6) 
NS 
CMV-positive 
OKT3 no OKT3 
2 5 
2/2 (100) 4/5 (80) 
NS 






rate of patients who developed invasive CMV dis-
ease was similar for patients who had received 
OKT3 and for those who had not (3/10 vs. 2/11, 
p=0.05). 
Adequate pretransplant serologic specimens for 
CMV were available from 35 of the 65 patients 
(Table 1). Eighty percent (28/35) were seronegative 
prior to transplantation. OKT3 therapy was associ-
ated with an increased overall incidence of primary 
CMV infection (58% vs. 25% p=0.08) and invas-
ive primary CMV disease (58% vs. 19% p=0.04). 
Four deaths occurred following primary invasive 
disease. Clinical CMV infection occurred in 6 of 
the 7 patients who were seropositive prior to trans-
plantation. Five of these patients developed invas-
ive CMV disease but none of them died. OKT3 
therapy did not appear to affect the CMV infection 
rate in this small group of patients. Techniques 
were not available to determine whether these in-
fections represented reactivation of latent CMV 
or whether they represented new onset primary 
infections with different strains of CMY. 
The omission of CMV serologic samples prior 
to transplant in 30 of the patients may result in a 
possible sampling error in the analysis of the effect 
of OKT3 therapy on CMV infection. The 35 pa-
tients from whom samples were obtained were 
comparable to those for whom samples were un-
available with respect to age (4.6 vs. 5.7 yr) and 
body size (16.1 vs. 19.4 kg). The first group was 
observed to have insignificantly increased rates of 
OKT3 therapy (14/35 vs. 8/30, p = 0.38), invasive 
CMV disease (15/35 vs. 6/30, p=0.09), and mor-
tality (8/35 vs. 3/30, p = 0.30). 
Only 1 patient received a liver transplant from 
a seropositive donor. She subsequently developed 
primary CMV hepatitis after a course of OKT3 
but recovered satisfactorily following ganciclovir 
therapy. 
Gancic10vir was administered to 12 of the 21 
patients with invasive CMV disease, including 5 
who died. The proportion of patients treated with 
gancic10vir was similar among patients who re-
ceived OKT3 (60%) and those who did not (55%). 
The case-fatality rate was not altered by ganciclovir 
therapy among patients who received OKT3 (3/6) 
and those who did not (2/6). 
Adenovirus 
Adenoviral infections occurred in 5 patients, 4 of 
whom developed invasive disease. Three of the 4 
received OKT3 and 2 had also been retransplanted. 
Hepatitis was present in all 4 patients with invasive 
infection. The 3 fatalities occurred in patients who 
developed disseminated infection with pneumonia. 
The serotypes in these patients were type 1 (2 cases) 
OKT3 and viral disease in liver Tx 
and type 2 (1 case). The serotype for the surviving 
patient with isolated adenoviral hepatitis, as well 
as an additional patient with a positive urine cul-
ture but no evidence of invasive disease, was type 
5. An increased incidence of invasive infection with 
adenovirus was seen in those patients who received 
OKT3 compared with those who did not (14% vs. 
2% p=O.l1). Retransplantation was also associ-
ated with a trend towards a higher incidence of 
invasive infection (17% vs. 4% p=0.09). 
Other viral infections 
The incidence of HSV infection was similar be-
tween those patients who received OKT3 and those 
who did not (14% vs. 9%). Two of 22 patients 
treated and 3 of 43 not treated with OKT3 de-
veloped infection with RSY. One patient with RSV, 
who had received OKT3 and had also undergone 
retransplantation for a thrombosed hepatic artery, 
died of severe RSV pneumonia. A 2nd patient who 
had not received OKT3 developed an acute episode 
of croup severe enough to require intubation and 
was found to have a positive enzyme immunoassay 
for RSV. The remaining 3 patients with RSV infec-
tion had only mild symptoms. Three patients de-
veloped EBV -associated PTLD: 2 fatal cases oc-
curred concomitant with invasive disseminated ad-
enovirus in patients treated with OKT3 who had 
undergone retransplantation; 1 nonfatal case oc-
curred in a patient with a single transplant who 
did not receive OKT3. One patient succumbed to 
disseminated enterovirus and polymicrobial sepsis 
following transmission of enterovirus from the do-
nor liver. 
Other factors 
The role of antecedent and/or synergistic infection 
was evaluated in the 27 patients who developed 
Table 2. Comparison of viral infections in adults and children following liver 
transplantation at the University of Pittsburgh 
Adults (13) Children 
Viral infection 53% (54/101) 58% (38/65) 
Severe infection' 24% (241'101) 42% (27/65) 
Case-fatality rate 37% (9/24) 37% (10/27) 
Viral infection 
OKT3 therapy 76% (+) 73% (16/22) 
no OKT3 46% (+) 51 % (22/43) 
significance p<0.05 p= 0.08 
Severe infection 
OKT3 therapy 27% (+) 59% (13/22) 
no OKT3 23% (+) 33% (14/43) 
significance p=NS p=0.04 
• "severe infection" in ref. 13 is defined similar to "invasive disease" herein. 
+ not reported. 
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invasive viral disease. All but 4 patients acquired 
a total of 55 antecedent/synergistic infections, in-
cluding 17 viral, 9 fungal and 29 bacterial. The 
sources of the bacterial infections were intra-ab-
dominal (10), catheter-line sepsis due to coagulase-
negative Staphylococcus (6), pneumonia (5) and 
various other sites (8). There was no difference in 
the frequency of antecedent/synergistic infections 
between those who had received OKT3 (27 epi-
sodes in 13 patients) and those who had not re-
ceived OKT3 (28 episodes in 14 patients). 
Abdominal surgery had been performed in 44 
patients prior to transplantation. The incidence of 
invasive viral disease was similar for this group 
and for those who did not have prior abdominal 
surgery (19/44 vs. 8/31, p=0.19). Also, the mor-
tality rate was similar for both groups (8/44 vs. 3/ 
31, p=0.49). Among the 27 patients with invasive 
viral disease, the proportion with a history of prior 
abdominal surgery was the same for those who had 
received OKT3 and for those who had not (8/13 
vs. 10/14). Previous abdominal surgery did not 
appear to affect the incidence of invasive viral dis-
ease or the role of OKT3 therapy on these infec-
tions. 
Discussion 
This study identifies the use of OK T3 as a signifi-
cant risk for invasive viral disease and mortality in 
liver transplant recipients. Results from this study 
also demonstrate increased primary invasive CMV 
disease following OKT3 therapy in these patients. 
Complications arising from invasive viral disease 
accounted for nearly all the deaths beyond the 1st 
postoperative week in this series. Our results also 
suggest that retransplantation is associated with 
increased viral infection and invasive viral disease. 
Table 3. CMV infection in liver transplant reCipients at University of Pittsburgh 















1981-8324 1984-8525 1983-8414 1987 
18 93 
12/18 (66) 55/93 (59) 
4118 (22) 11/93 (12) 
4112 (33) 12/55 (22) 
o 53/93 (57) 
18 93 
8118 (44) 37/93 (40) 
5/8 (62) 17/37 (46) 
2/8 (25) 8/37 (22) 
10/18 (56) 56/93 (60) 
7/10 (70) 38/56 (67) 
2/10 (20) 3/56 (5) 
43 65 
13/43 (30) 26/65 (40) 
3/43 (7) 21/65 (32) 
1/13 (8) 5/26 (19) 
o 22/65 (34) 
43 35 
35/43 (81) 28/35 (80) 
6/35 (17) 11/28 (39) 
2/35 (6) 10/28 (36) 
8/43 (19) 7/35 (20) 
7/8 (88) 6/7 (86) 
1/8 (12) 5/7 (71) 
This study is limited by several methodological 
problems which could affect the clinical impli-
cations of the results. As a retrospective investiga-
tion, randomized controls were unavailable. The 
risk factors OKT3 and retransplantation are thera-
peutic options which were applied in a nonrandom 
fashion based upon clinical judgment. Further, it 
was not possible to control differences in the over-
all level of immunosuppression between patient 
groups. However, it was the practice of the trans-
plant team to maintain similar doses and levels 
of immunosuppression in all patients. The size of 
comparison groups in this study was small, reduc-
ing the strength of our observations. Finally, the 
availability of only about half of the patients for 
pretransplant CMV serologic analysis may not be 
representative of the entire study popUlation. 
Occasional reports have described viral infection 
as a complication of OKT3 use following liver 
transplantation. In one randomized trial (22) of 
OK T3 compared to steroids for treatment of acute 
rejection in 28 liver transplant recipients, there was 
no significant difference in the rate of viral infec-
tion between the two groups (33% vs. 23%). In an 
earlier study (23) of 80 pediatric liver transplant 
recipients who received either OKT3 or steroid 
therapy for acute rejection, there were no signifi-
cant differences between the two groups in the rates 
of viral infection, retransplantation, or mortality. 
A review (13) of 101 adult liver transplant recipi-
ents reported a higher overall viral infection rate 
following OKT3 therapy (76% vs. 46% p < 0.05) 
but there was no difference in the incidence of 
severe viral disease (27% vs. 23%). In a compari-
son of viral infection rates between our pediatric 
patients and the adults reported by Kusne et al. 
(Table 2), the overall viral infection rates are about 
equal. However, there is a disproportionate in-
crease in invasive viral disease within the pediatric 
population following OKT3 therapy. 
CMV is the most common viral infection in liver 
transplant recipients (3). The results of four differ-
ent series of pediatric and adult liver transplant 
recipients from this institution are summarized in 
Table 3 (14, 24, 25). The increased infection rate 
of invasive CMV seen in children following the 
introduction of OKT3 was not observed in adults. 
The differential effect of OKT3 on children may 
be accounted for by differences in the pretransplant 
CMV serologic status in these two groups of pa-
tients. Whereas only 20% of pediatric patients were 
CMV seropositive, 60% of adults were seroposi-
tive. Since only primary CMV disease appeared to 
be increased by the use of OKT3, it is not surpris-
ing that children were more adversely affected than 
adults. The comparatively low rates of CMV sero-
positivity among our pediatric recipients and do-
• 2 
nors are reflective of the younger popUlation (less 
than 3 yr old) from which the majority of these 
recipients (and donors) were drawn. 
The major sources of transmission of CMV in-
fections in transplant recipients are the donor or-
gans and blood transfusions (1, 26-29). However, 
in a previous report (14) only 3 of 35 seronegative 
pediatric patients received allografts from seroposi-
tive donors; 1 of these subsequently developed 
CMV infection. In the current study only I donor 
was CMV -seropositive. This suggests that the ma-
jor source of primary CMV infections seen in these 
two series was the administration of blood prod-
ucts. The risk of acquiring primary CMV infection 
from blood transfusions in children is 2.7% per 
unit (30). The average volume of packed red cells 
transfused intraoperatively during pediatric liver 
transplantation at this hospital was 10 units (31). 
Blood products were not screened for CMV anti-
bodies during the study period. Based upon these 
data, our current policy is to use CMV -negative 
blood products in all seronegative pediatric liver 
transplant recipients. 
Adenovirus is a known cause of approximately 
5 to 10% of upper respiratory tract infections in the 
general pediatric popUlation (32). Sporadic reports 
(33) have identified severe fulminant infection 
caused by adenovirus in immunocompromised 
hosts. A previous report (34) from this institution 
described a nearly identical incidence of adenoviral 
infections (8%) in 22 of 262 pediatric liver trans-
plant recipients between 1981 and 1986. The cur-
rent study provides further confirmation of the 
importance of adenovirus in pediatric liver trans-
plant recipients and the possible impact of prior 
OKT3 therapy. 
The identification of OKTJ therapy alone or in 
combination with retransplantation as a risk factor 
for increased morbidity and mortality from viral 
infections among pediatric liver transplant recipi-
ents with steroid-resistant acute rejection suggests 
the need for strategies to minimize its impact. It 
is unclear whether retransplantation may simply 
reflect the increased immunosuppression associ-
ated with a second induction (other than OKT3), 
or whether the second operation itself predisposes 
to infection. However, since there are no available 
alternatives to retransplantation, a cautious ap-
proach to the use of OKT3 is indicated. A biopsy 
which confirms rejection should be a prerequisite 
to the use ofOKT3. The substitution ofOKT3 for 
the usual steroid pulse-tapered cycle early in the 
course of acute rejection would eliminate any con-
tributory component of additional steroids on the 
rate of infectious complications in this setting. The 
reduction of immunosuppression when a patient 
acquires one or both of these risk factors should 
OKT3 and viral disease in liver Tx 
be considered, recognizing that reduction of im-
munosuppression at the time of retransplantation 
may lead to rapid and severe rejection of the new 
allograft. However, in some centers the standard 
immunosuppression is often reduced or eliminated 
during the early course of OKT3 therapy (12). The 
risk of "rebound rejection" upon completion of 
OKT3 is reported to be high unless overall im-
munosuppression is returned to therapeutic levels 
during the last several days of this therapy (17). 
CMV prophylaxis is another option in patients 
who are receiving OKT3. Based upon recent opti-
mistic reports describing anti-CMV therapy 
(35-40), the administration of anti-CMV immuno-
globulin, acyclovir, or gancic10vir may be effective 
as a prophylactic strategy among seronegative liver 
transplant recipients who subsequently undergo a 
course of OKT3 and/or retransplantation. 
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